Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An eastern cooperative oncology group study

John M. Bennett, Mary S. Young, Jane L. Liesveld, Elisabeth Paietta, Kenneth B. Miller, Hillard M. Lazarus, Robert D. Marsh, William R. Friedenberg, Hussain T. Saba, F. Ann Hayes, Gordon W. Dewald, Wolfgang Hiddemann, Jacob M. Rowe

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An eastern cooperative oncology group study'. Together they form a unique fingerprint.

Medicine & Life Sciences